Parkinson's disease: prospects for improved drug therapy
- 1 July 1997
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 18 (4), 156-163
- https://doi.org/10.1016/s0165-6147(97)90612-x
Abstract
No abstract availableThis publication has 44 references indexed in Scilit:
- Does levodopa therapy delay death in Parkinson's disease? A review of the evidenceMovement Disorders, 1995
- Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophreniaBiological Psychiatry, 1993
- Is levodopa harmful?The Lancet, 1991
- “Early” initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's diseaseNeurology, 1991
- Nigrostriatal Damage is Required for Induction of Dyskinesias by l-DOPA in Squirrel MonkeysClinical Neuropharmacology, 1990
- Young onset Parkinson's diseaseMovement Disorders, 1987
- Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapyNeurology, 1979
- SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASEThe Lancet, 1977
- ParkinsonismNeurology, 1967
- Aromatic Amino Acids and Modification of ParkinsonismNew England Journal of Medicine, 1967